Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia

NCT07175493 is registered in ClinicalTrials.gov with Keymed Biosciences Co.Ltd as lead sponsor.

NCT NCT07175493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07175493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia
Lead sponsor
Keymed Biosciences Co.Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 18, 2025
Completion date
November 18, 2028
Enrollment
158 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune cytopenia, autoimmune hemolytic anemia, evans syndrome, immune thrombocytopenia (itp)